Harmony Biosciences Holdings, Inc. (HRMY) stock
HRMYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 18/3039% below fair value
$32.98−0.13 (-0.39%)
Close on Nov 19, 2026Market cap $1.92BP/E 10.7Yield –
Harmony Biosciences revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Harmony Biosciences's revenue for the twelve months ending Jun 30, 2026 was $959.90M, up 24.3% year over year. For fiscal 2025 it was $868.45M, up 21.5% from the year before. The highest annual figure on record is $868.45M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $868.45M | +21.5% |
| FY2024 | Dec 31, 2024 | $714.73M | +22.8% |
| FY2023 | Dec 31, 2023 | $582.02M | +32.9% |
| FY2022 | Dec 31, 2022 | $437.86M | +43.4% |
| FY2021 | Dec 31, 2021 | $305.44M | +91.2% |
| FY2020 | Dec 31, 2020 | $159.74M | +2564.6% |
| FY2019 | Dec 31, 2019 | $6.00M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $261.28M | +30.3% |
| Q1 FY2026 | Mar 31, 2026 | $215.39M | +16.6% |
| Q4 FY2025 | Dec 31, 2025 | $243.78M | +21.1% |
| Q3 FY2025 | Sep 30, 2025 | $239.46M | +28.7% |
| Q2 FY2025 | Jun 30, 2025 | $200.49M | +16.0% |
| Q1 FY2025 | Mar 31, 2025 | $184.73M | +19.5% |
| Q4 FY2024 | Dec 31, 2024 | $201.27M | +19.5% |
| Q3 FY2024 | Sep 30, 2024 | $186.04M | +16.1% |
| Q2 FY2024 | Jun 30, 2024 | $172.81M | +28.8% |
| Q1 FY2024 | Mar 31, 2024 | $154.62M | +29.8% |
| Q4 FY2023 | Dec 31, 2023 | $168.41M | +31.3% |
| Q3 FY2023 | Sep 30, 2023 | $160.27M | +36.7% |
| Q2 FY2023 | Jun 30, 2023 | $134.22M | +25.4% |
| Q1 FY2023 | Mar 31, 2023 | $119.13M | +39.6% |
| Q4 FY2022 | Dec 31, 2022 | $128.31M | +40.7% |
| Q3 FY2022 | Sep 30, 2022 | $117.21M | +45.2% |
| Q2 FY2022 | Jun 30, 2022 | $107.03M | +45.0% |
| Q1 FY2022 | Mar 31, 2022 | $85.31M | +43.0% |
| Q4 FY2021 | Dec 31, 2021 | $91.21M | +62.0% |
| Q3 FY2021 | Sep 30, 2021 | $80.73M | +77.0% |
| Q2 FY2021 | Jun 30, 2021 | $73.82M | +94.2% |
| Q1 FY2021 | Mar 31, 2021 | $59.67M | +200.8% |
| Q4 FY2020 | Dec 31, 2020 | $56.29M | – |
| Q3 FY2020 | Sep 30, 2020 | $45.61M | – |
| Q2 FY2020 | Jun 30, 2020 | $38.01M | – |
| Q1 FY2020 | Mar 31, 2020 | $19.84M | – |
See a number that looks wrong?